title: Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival.
abstract: Syndecan-1 (CD138) is a heparin sulphate proteoglycan that is over expressed on the surface of both normal and malignant plasma cells and actively shed from the cell surface (soluble syndecan-1). Soluble syndecan-1 has been shown to be an independent prognostic factor in myeloma but its role in prognostic classification requires further investigation. We have retrospectively measured soluble syndecan-1 in 324 presentation samples and 154 plateau phase samples from the UK Medical Research Council Myeloma VIth trial. Log-rank analysis showed that the presentation value of soluble syndecan-1 is a highly significant prognostic factor when assessing survival from entry (chi2=14.92, P<0.0001) and remains an important independent prognostic factor when considered in Cox regression models (P<or=0.02) with known independent factors. The magnitude of fall in soluble syndecan-1 from presentation to plateau also had prognostic value when assessing overall survival from plateau (chi2=3.79, P=0.05). In conclusion, this large study confirms that soluble syndecan-1 level is a powerful independent prognostic factor both at diagnosis and at plateau phase.
authors.affiliation: Department of Haematology, Birmingham Heartlands Hospital, Birmingham, UK.
authors.forename: Richard
authors.initials: R
authors.lastname: Lovell
authors.forename: Janet A
authors.initials: JA
authors.lastname: Dunn
authors.forename: Gulnaz
authors.initials: G
authors.lastname: Begum
authors.forename: Nicola J
authors.initials: NJ
authors.lastname: Barth
authors.forename: Tim
authors.initials: T
authors.lastname: Plant
authors.forename: Paul A
authors.initials: PA
authors.lastname: Moss
authors.forename: Mark T
authors.initials: MT
authors.lastname: Drayson
authors.forename: Guy
authors.initials: G
authors.lastname: Pratt
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D016009:Chi-Square Distribution; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008562:Membrane Glycoproteins / Q000097:blood*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000401:mortality; D011379:Prognosis; D011509:Proteoglycans / Q000097:blood*; D012189:Retrospective Studies; D015996:Survival Rate; D053668:Syndecan-1; D053667:Syndecans
chemical_list: D014408:Biomarkers, Tumor; D008562:Membrane Glycoproteins; D011509:Proteoglycans; C508241:SDC1 protein, human; D053668:Syndecan-1; D053667:Syndecans